NATIONAL CLINICAL RESEARCH NETWORK TO SUPPORT DRUG RESEARCH AND DEVELOPMENT (AML)
- Experts' advice
- AML
- Targeted therapy
- Cell therapy
- Immunotherapy
- Hematopoietic stem cell transplant
- Clinical research (TRL 3-8)
With many years of expertise in conducting clinical and translational studies, ALFA Group's experts can help you establish a research and development strategy for innovative treatments in acute myeloid leukemia (AML).
In the context of regulatory, clinical, medico-economic and market access issues, ALFA guides you in the construction of your treatment development plan, including the evaluation of new therapeutic combinations.
Description
Scope
Our consulting services include:
- Personalized support, adapted to the development stage, from preclinical and correlative studies (in liaison with the network's translational laboratories) to registration trials, including early phase I/II trials.
- The provision of clinical, scientific and regulatory expertise, and market knowledge
Setting up support
- Multidisciplinary advisory boards
- Defining the elements of identified partnerships. These may take the form of expert reports, translational study projects, or even clinical trials
- Drafting of roadmaps, study projects and related reports
Organization
- Dr. Renaud Buffet, Medical Coordination
- Prof. Raphaêl Itzykson, President of the Scientific Council
Quality assurance
- Traceability of all stages of collaboration
Specifications
Therapeutic approach: Chemotherapy; Targeted therapy; Immunotherapy; Cell therapy-Hematopoietic stem cell transplantation
Development phases: I-IV
Support steps:
- Multidisciplinary advisory boards
- Definition of identified partnership elements. These may vary widely, and take the form of expert reports, translational study projects or even clinical trials
- Drafting of roadmaps, study projects and related reports
Examples of partnerships
Biomarkers study in relapsing/refractory AMLpatientsOrg - Expression of original markers of leukemic cells and potential targets of immunotherapeutic agents from patients with AML refractory to or relapsing after a first-line therapy and enrolled in ALFA-PPP study.
Partner: Advesya
Terms
- Consulting contract
OPALE entity
Acute Leukemia French Association (ALFA)
Head of Entity
Contact
Dr. Sandrine PalcyBusiness Development Director
Other offers
NATIONAL CLINICAL RESEARCH NETWORK FOR THE DESIGN, SPONSORING AND CONDUCT OF PHASE I-IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (AML)
NATIONAL CLINICAL RESEARCH NETWORK TO SUPPORT SPONSORS OF PHASE I TO IV INTERVENTIONAL AND NON-INTERVENTIONAL CLINICAL TRIALS (AML)
DATA AND SAMPLES FROM ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)